SciBX: Science-Business eXchange Contents: April 12 2012, Volume 5 / Issue 15

TABLE OF CONTENTS April 12 2012, Volume 5 / Issue 15 Analysis Cover Story Translational Notes Targets and Mechanisms Tools The Distillery: Therapeutics Autoimmune disease Cancer Cardiovascular disease Endocrine/metabolic disease Infectious disease Neurology Renal disease The Distillery: Techniques Assays and screens Computational models Disease models Drug platforms Imaging SciBX: Science-Business eXchange Recommend SciBX to your library today SciBx is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing. For more information visit: www.nature.com/scibx.   Trade Secrets A Nature Network blog by BIOENTREPRENEUR Brought to you by Nature Biotechnology Access the insights, advice and commentary from scientists and entrepreneurs building biotech sectors around the world. Join the global dialogue on life science entrepreneurship: http://blogs.nature.com/trade_secrets   Analysis Cover Story Top Targeting CDK in triple-negative breast cancer Kai-Jye Lou doi:10.1038/scibx.2012.379 UCSF researchers have found that the majority of triple-negative breast cancers have a dysregulated MYC pathway, and the group has shown that CDK inhibitors such as Merck and Ligand's dinaciclib could selectively kill off these tumors. The group is planning a clinical trial to test an undisclosed CDK inhibitor in this patient population. Full Text | PDF Translational Notes Top Phenotypic screening, take two Joanne Kotz doi:10.1038/scibx.2012.380 Phenotypic screening for drug discovery is making a comeback, but not everybody is embracing it. Some pharmas, such as Novartis and GSK, are placing a bet on phenotypic screening, whereas others, such as Genentech, are staying focused on target-based screening. Full Text | PDF Targets and Mechanisms Top DEL1: taking the bite out of periodontitis Michael J. Haas doi:10.1038/scibx.2012.381 An international team of researchers has used the endothelial protein DEL1 to treat periodontitis in mice. Despite the therapeutic angle, the near-term utility of DEL1 is more likely as a diagnostic and risk marker for the disease. Full Text | PDF Tools Top Letting go of inhibition Lev Osherovich doi:10.1038/scibx.2012.382 UCSF researchers have created a class of reversible, covalent small molecule kinase inhibitors that could be more selective and safer than previous kinase inhibitors. Principia Biopharma has exclusively licensed the technology and hopes to develop new compounds to treat cancer and autoimmune diseases. Full Text | PDF Distillery: Therapeutics Autoimmune disease Top Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa; HspA5; GRP78) doi:10.1038/scibx.2012.383 Patient sample and mouse studies suggest inhibiting GRP78 could help treat RA. Full Text | PDF Cancer Top B cell lymphoma 2 (BCL-2; BCL2); BCL2-like 11 apoptosis facilitator (BCL2L11; BIM) doi:10.1038/scibx.2012.384 Mouse and patient sample studies suggest inhibiting BCL-2 could help improve the efficacy of Nexavar sorafenib against AML. Full Text | PDF Cyclin dependent kinase (CDK) doi:10.1038/scibx.2012.385 Mouse and cell culture studies suggest CDK inhibitors could help treat triple-negative breast cancer. Full Text | PDF Epidermal growth factor receptor (EGFR); HER2 (EGFR2; ERBB2; neu) doi:10.1038/scibx.2012.386 Mouse and cell culture studies identified pyrrolo[3,2-d]pyrimidine-based dual inhibitors of HER2 and EGFR that could help treat cancer. Full Text | PDF Tankyrase TRF1-interacting ankyrin-related ADP-ribose polymerase (TNKS) doi:10.1038/scibx.2012.387 Mouse and cell culture studies identified a TNKS inhibitor that could help treat cancer. Full Text | PDF β-Catenin (CTNNB1) doi:10.1038/scibx.2012.388 Mouse studies suggest inhibiting CTNNB1 could help treat CML. Full Text | PDF Mammalian target of rapamycin (mTOR; FRAP; RAFT1) doi:10.1038/scibx.2012.389 A study in patients with renal cancer suggests that high levels of tumor heterogeneity could pose a challenge for personalized cancer medicine. Full Text | PDF Cardiovascular disease Top Not applicable doi:10.1038/scibx.2012.390 Mouse studies suggest improving autophagy in atherosclerotic lesions could help reduce disease severity. Full Text | PDF Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2) doi:10.1038/scibx.2012.391 Mouse studies suggest fumarate compounds could help treat cardiac ischemia/reperfusion injury. Full Text | PDF Endocrine/metabolic disease Top p75 Neurotrophin receptor (p75 NTR) doi:10.1038/scibx.2012.392 In vitro and mouse studies suggest inhibiting p75 NTR could help treat type 2 diabetes. Full Text | PDF Infectious disease Top Not applicable doi:10.1038/scibx.2012.393 A study in mice identified 3-carboxyl-4(1H)-quinolone compounds that could help treat malaria. Full Text | PDF Neurology Top Phosphorylated-τ 231 (p-t 231) doi:10.1038/scibx.2012.394 In vitro and mouse studies identified antibodies against the cis conformation of p-t 231 that could help treat or diagnose AD. Full Text | PDF Not applicable doi:10.1038/scibx.2012.395 Cell culture and mouse studies suggest human embryonic stem cell (hESC)-derived neural progenitors could be used to treat HD. Full Text | PDF Serotonin (5-HT3) receptor doi:10.1038/scibx.2012.396 Studies in mice suggest 5-HT3 receptor antagonists could help treat anorexia. Full Text | PDF Renal disease Top Transglutaminase 2 (TGM2; TG2) doi:10.1038/scibx.2012.397 In vitro and mouse studies suggest inhibiting TG2 could help treat IgA-induced nephropathy. Full Text | PDF Distillery: Techniques Assays and screens Top Combinatorial libraries for unbiased identification of CD8+ T cell target antigens doi:10.1038/scibx.2012.398 Combinatorial libraries of short peptides could help identify CD8+ T cell antigens and guide development of vaccines and immunotherapies. Full Text | PDF Computational models Top Statistical model for assessing the predictive capacity of personal genome sequencing doi:10.1038/scibx.2012.399 A statistical model suggests whole-genome sequencing has limited utility in assessing disease risk. Full Text | PDF Disease models Top Humanized immune mouse model for personalized medicine doi:10.1038/scibx.2012.400 A mouse model of the human immune response could help evaluate new immunotherapies. Full Text | PDF Mice that express human Fc γ-receptor (FCGR) doi:10.1038/scibx.2012.401 Mice that express human FCGRs could be useful models of antibody-mediated immune responses. Full Text | PDF Drug platforms Top Leukemia-specific T cell therapy using zinc finger nuclease (ZFN) T cell editing doi:10.1038/scibx.2012.402 In vitro and mouse studies identified a ZFN-based method of T cell cancer therapy. Full Text | PDF Reversible cysteine-modifying kinase inhibitors doi:10.1038/scibx.2012.403 In vitro studies suggest reversible cysteine-modifying kinase inhibitors could have better specificity and safety than irreversible kinase inhibitors. Full Text | PDF Imaging Top 18F-labeled nitroimidazole-1,4,7-triazacyclononane-1,4-diacetic acid (NODA) conjugate for hypoxia imaging doi:10.1038/scibx.2012.404 In vitro and mouse studies identified a PET imaging agent that could be useful as a cancer diagnostic. Full Text | PDF You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.